Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium

SAN DIEGO and CALGARY, AB: IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC SAN DIEGO and CALGARY, AB, Nov. 19, 2021 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present an update on the Phase 2 IRENE trial in a poster at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is taking place December 7 – 10, 2021, both virtually and in-person, at the Henry B. González Convention Center in San Antonio, Texas. Details on the poster and its corresponding abstract, available on the SABCS website, are shown below.
Click here to view original post